Rapport Therapeutics, Inc. Common Stock (RAPP) vs Taysha Gene Therapies, Inc. (TSHA)
A side-by-side comparison of Rapport Therapeutics, Inc. Common Stock and Taysha Gene Therapies, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
RAPP
Rapport Therapeutics, Inc. Common Stock
$30.78HealthcareDelayed quote: Oct 6, 2026, 3:30 PM EDT
TSHA
Taysha Gene Therapies, Inc.
$4.41HealthcareDelayed quote: Oct 6, 2026, 3:30 PM EDT
Total return — RAPP vs TSHA
growth of $100 · dividends reinvested · last 2yRAPP +54.8% (+24.4%/yr)TSHA +16.3% (+7.9%/yr)RAPP compounded faster over this window
RAPP TSHA
RAPP vs TSHA: by the numbers
- •RAPP is the larger company ($1.47B vs $1.41B market cap).
- •Both run net losses; RAPP's is the smaller (-685.80% vs -2728.04% net margin).
Metrics side by side
Valuation
| Metric | RAPP | TSHA |
|---|---|---|
| P/S ratio | 73.60 | 256.88 |
| P/B ratio | 3.48 | 3.64 |
Profitability
| Metric | RAPP | TSHA |
|---|---|---|
| Gross margin | 0.00% | 100.00% |
| Operating margin | 0.00% | -1130.65% |
| Net margin | -685.80% | -2728.04% |
| ROE | -32.43% | -38.64% |
| ROIC | -35.66% | -34.46% |
Growth (annualized)
| Metric | RAPP | TSHA |
|---|---|---|
| Total return CAGR (5Y) | N/A | -25.17% |
Go deeper
Dig into the metrics
Rapport Therapeutics, Inc. Common Stock ROETaysha Gene Therapies ROERapport Therapeutics, Inc. Common Stock operating marginTaysha Gene Therapies operating marginRapport Therapeutics, Inc. Common Stock revenue growthTaysha Gene Therapies revenue growthRapport Therapeutics, Inc. Common Stock free cash flowTaysha Gene Therapies free cash flow
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.